Skip to main content
Top
Published in: Infection 6/2015

01-12-2015 | Original Paper

Bacteremic pneumococcal pneumonia: clinical outcomes and preliminary results of inflammatory response

Authors: J. M. Bordon, R. Fernandez-Botran, T. L. Wiemken, P. Peyrani, S. M. Uriarte, F. W. Arnold, L. Rodriquez-Hernandez, M. J. Rane, R. R. Kelley, L. E. Binford, S. Uppatla, R. Cavallazzi, F. Blasi, S. Aliberti, M. I. Restrepo, S. Fazeli, A. Mathur, M. Rahmani, K. Ayesu, J. Ramirez

Published in: Infection | Issue 6/2015

Login to get access

Abstract

Purpose

Further examination of clinical outcomes and inflammatory response of bacteremic pneumococcal community-acquired pneumonia (CAP) is of great interest to enhance the care of patients with pneumococcal CAP.

Methods

This is a secondary analysis of the Community Acquired Pneumonia Organization (CAPO) to compare the time to clinical stability (TCS), length of hospital stay (LOS), and in-hospital mortality of hospitalized pneumococcal CAP patients with and without bacteremia. To measure the effect of bacteremia in pneumococcal CAP patients on outcomes, we modeled all-cause in-hospital mortality using a Poisson regression model, and TCS and LOS using Cox proportional hazards models. Adjusted multivariate regression models were also used to predict the probability of occurrence of each of the study outcomes. To investigate the inflammatory response, we measured the plasma levels of pro- and anti-inflammatory cytokines [tumor necrosis factor (TNF)-α, interleukin (IL)-1rα, IL-6, IL-8, IL-10], inflammatory biomarkers [C-reactive protein (CRP), pro-calcitonin (PCT), and B-type natriuretic peptide (BNP)], and peripheral blood neutrophil responses in 10 patients, 4 bacteremic and 6 non-bacteremic pneumococcal CAP, upon admission and every other day during the first 6 days of hospitalization. Functional data were presented as median and standard error of the median (SEM); due to small number of samples no statistical comparisons were performed between groups.

Results

From 833 pneumococcal CAP patients, 394 patients (47 %) were bacteremic. Bacteremic pneumococcal CAP were less likely to reach TCS with an adjusted hazard ratio (AHR) of 0.82 (95 % CI 0.69–0.97; p = 0.02) and had higher in-hospital mortality with an AHR of 1.63 (95 % CI 1.06–2.50, p = 0.026). Bacteremic pneumococcal CAP patients had a longer LOS than non-bacteremic pneumococcal CAP (p < 0.003). Higher plasma levels of CRP, PCT, and BNP were found in bacteremic than in non-bacteremic patients. The bacteremic group had consistently higher plasma levels of both pro- and anti-inflammatory cytokines. The blood neutrophil functional responses were similar in both groups of patients.

Conclusions

Bacteremic pneumococcal CAP patients were significantly associated with higher in-hospital mortality, lower TCS, and longer LOS. HIV-infected patients showed a greater mortality which was not statistically significant. Bacteremic pneumococcal CAP patients had higher levels of biomarkers and systemic cytokines.
Appendix
Available only for authorised users
Literature
1.
go back to reference Heffron R. Pneumonia, with special reference to pneumococcus lobar pneumonia. Cambridge: Harvard University Press; 1939. Heffron R. Pneumonia, with special reference to pneumococcus lobar pneumonia. Cambridge: Harvard University Press; 1939.
2.
go back to reference Moberley S, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;1:CD000422.PubMed Moberley S, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;1:CD000422.PubMed
3.
go back to reference Griffin MR, et al. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. New Engl J Med. 2013;369:155–63.CrossRefPubMed Griffin MR, et al. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. New Engl J Med. 2013;369:155–63.CrossRefPubMed
4.
go back to reference Nuorti JP, et al. Cigarette smoking and invasive pneumococcal disease. Active bacterial core surveillance team. New Engl J Med. 2000;342:681–9.CrossRefPubMed Nuorti JP, et al. Cigarette smoking and invasive pneumococcal disease. Active bacterial core surveillance team. New Engl J Med. 2000;342:681–9.CrossRefPubMed
5.
go back to reference Musher DM, et al. Bacteremic and nonbacteremic pneumococcal pneumonia. Prospect Study Med. 2000;79:210–21. Musher DM, et al. Bacteremic and nonbacteremic pneumococcal pneumonia. Prospect Study Med. 2000;79:210–21.
6.
go back to reference Song JH, et al. Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in asian countries: a study by the Asian network for surveillance of resistant pathogens. Clin Infect Dis Off Publ Infect Dis Soc Am. 2004;38:1570–8.CrossRef Song JH, et al. Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in asian countries: a study by the Asian network for surveillance of resistant pathogens. Clin Infect Dis Off Publ Infect Dis Soc Am. 2004;38:1570–8.CrossRef
7.
go back to reference Garcia-Vidal C, et al. Early mortality in patients with community-acquired pneumonia: causes and risk factors. Eur Respir J. 2008;32:733–9.CrossRefPubMed Garcia-Vidal C, et al. Early mortality in patients with community-acquired pneumonia: causes and risk factors. Eur Respir J. 2008;32:733–9.CrossRefPubMed
8.
go back to reference Lin SH, et al. Outcomes of hospitalized patients with bacteraemic and non-bacteraemic community-acquired pneumonia caused by Streptococcus pneumoniae. Epidemiol Infect. 2011;139:1307–16.CrossRefPubMed Lin SH, et al. Outcomes of hospitalized patients with bacteraemic and non-bacteraemic community-acquired pneumonia caused by Streptococcus pneumoniae. Epidemiol Infect. 2011;139:1307–16.CrossRefPubMed
9.
go back to reference Fine MJ, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA J Am Med Assoc. 1996;275:134–41.CrossRef Fine MJ, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA J Am Med Assoc. 1996;275:134–41.CrossRef
11.
go back to reference Kang CI, et al. Risk factors and pathogenic significance of bacteremic pneumonia in adult patients with community-acquired pneumococcal pneumonia. J Infect. 2013;66:34–40.CrossRefPubMed Kang CI, et al. Risk factors and pathogenic significance of bacteremic pneumonia in adult patients with community-acquired pneumococcal pneumonia. J Infect. 2013;66:34–40.CrossRefPubMed
12.
go back to reference Bordon J, et al. The presence of pneumococcal bacteremia does not influence clinical outcomes in patients with community-acquired pneumonia: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study. Chest. 2008;133:618–24.CrossRefPubMed Bordon J, et al. The presence of pneumococcal bacteremia does not influence clinical outcomes in patients with community-acquired pneumonia: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study. Chest. 2008;133:618–24.CrossRefPubMed
13.
go back to reference Marrie TJ, Low DE, De Carolis E. A comparison of bacteremic pneumococcal pneumonia with nonbacteremic community-acquired pneumonia of any etiology–results from a Canadian multicentre study. Can Respir J J Can Thorac Soc. 2003;10:368–74. Marrie TJ, Low DE, De Carolis E. A comparison of bacteremic pneumococcal pneumonia with nonbacteremic community-acquired pneumonia of any etiology–results from a Canadian multicentre study. Can Respir J J Can Thorac Soc. 2003;10:368–74.
14.
go back to reference Lisboa T, et al. Radiologic progression of pulmonary infiltrates predicts a worse prognosis in severe community-acquired pneumonia than bacteremia. Chest. 2009;135:165–72.CrossRefPubMed Lisboa T, et al. Radiologic progression of pulmonary infiltrates predicts a worse prognosis in severe community-acquired pneumonia than bacteremia. Chest. 2009;135:165–72.CrossRefPubMed
15.
go back to reference Ramirez JA, Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia. Arch Intern Med. 2001;161:848–50.CrossRefPubMed Ramirez JA, Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia. Arch Intern Med. 2001;161:848–50.CrossRefPubMed
16.
go back to reference Borregaard N, Sorensen OE, Theilgaard-Monch K. Neutrophil granules: a library of innate immunity proteins. Trends Immunol. 2007;28:340–5.CrossRefPubMed Borregaard N, Sorensen OE, Theilgaard-Monch K. Neutrophil granules: a library of innate immunity proteins. Trends Immunol. 2007;28:340–5.CrossRefPubMed
17.
go back to reference Sheppard FR, et al. Structural organization of the neutrophil NADPH oxidase: phosphorylation and translocation during priming and activation. J Leukoc Biol. 2005;78:1025–42.CrossRefPubMed Sheppard FR, et al. Structural organization of the neutrophil NADPH oxidase: phosphorylation and translocation during priming and activation. J Leukoc Biol. 2005;78:1025–42.CrossRefPubMed
18.
go back to reference Antunes G, et al. Systemic cytokine levels in community-acquired pneumonia and their association with disease severity. Eur Respir J. 2002;20:990–5.CrossRefPubMed Antunes G, et al. Systemic cytokine levels in community-acquired pneumonia and their association with disease severity. Eur Respir J. 2002;20:990–5.CrossRefPubMed
19.
go back to reference Bordon J, et al. Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective vs. deleterious inflammatory response in pneumonia. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2013;17:e76–83. Bordon J, et al. Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective vs. deleterious inflammatory response in pneumonia. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2013;17:e76–83.
21.
go back to reference Arnold FW, et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med. 2007;175:1086–93.CrossRefPubMed Arnold FW, et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med. 2007;175:1086–93.CrossRefPubMed
22.
go back to reference Arnold FW, et al. Hospitalization for community-acquired pneumonia: the pneumonia severity index vs. clinical judgment. Chest. 2003;124:121–4.CrossRefPubMed Arnold FW, et al. Hospitalization for community-acquired pneumonia: the pneumonia severity index vs. clinical judgment. Chest. 2003;124:121–4.CrossRefPubMed
23.
go back to reference Fine MJ, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. New Engl Jo Med. 1997;336:243–50.CrossRef Fine MJ, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. New Engl Jo Med. 1997;336:243–50.CrossRef
24.
go back to reference Niederman MS, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730–54.CrossRefPubMed Niederman MS, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730–54.CrossRefPubMed
25.
go back to reference Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159:702–6.CrossRefPubMed Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159:702–6.CrossRefPubMed
27.
go back to reference Pereira JM, et al. Can we predict pneumococcal bacteremia in patients with severe community-acquired pneumonia? J Crit Care. 2013;28:970–4.CrossRefPubMed Pereira JM, et al. Can we predict pneumococcal bacteremia in patients with severe community-acquired pneumonia? J Crit Care. 2013;28:970–4.CrossRefPubMed
28.
go back to reference Christ-Crain M, et al. Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia. J Intern Med. 2008;264:166–76.CrossRefPubMed Christ-Crain M, et al. Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia. J Intern Med. 2008;264:166–76.CrossRefPubMed
Metadata
Title
Bacteremic pneumococcal pneumonia: clinical outcomes and preliminary results of inflammatory response
Authors
J. M. Bordon
R. Fernandez-Botran
T. L. Wiemken
P. Peyrani
S. M. Uriarte
F. W. Arnold
L. Rodriquez-Hernandez
M. J. Rane
R. R. Kelley
L. E. Binford
S. Uppatla
R. Cavallazzi
F. Blasi
S. Aliberti
M. I. Restrepo
S. Fazeli
A. Mathur
M. Rahmani
K. Ayesu
J. Ramirez
Publication date
01-12-2015
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 6/2015
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-015-0837-z

Other articles of this Issue 6/2015

Infection 6/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.